Trial to investigate multiple products simultaneously to accelerate development of new therapies for ALS
Study identifies kids with cancer at risk of developing lethal infections
12 July 2022Human catches COVID from a cat: Why this new evidence is not cause for panic
12 July 2022Trial to investigate multiple products simultaneously to accelerate development of new therapies for ALS
The HEALEY ALS Platform Trial led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital in collaboration with the Northeast ALS Consortium (NEALS) is a trial in which multiple investigational products are tested and evaluated simultaneously to accelerate the development of potential new therapies for people with Amyotrophic Lateral Sclerosis (ALS). Drug candidates that enter the platform trial are chosen by a group of expert ALS scientists and members of the Healey & AMG Center Science Advisory Committee. The Healey & AMG Center for ALS at Mass General and Calico Life Sciences LLC recently signed an agreement to work together to test ABBV-CLS-7262 in the HEALEY ALS Platform Trial.
